The Ibogaine Project

The Ibogaine Project aims to bring real therapeutic solutions to market by furthering the science behind the vast body of anecdotal and empirical knowledge of ibogaine.

Ibogaine is an atypical psychedelic substance that shows potential as an effective medicine for various indications. MINDCURE is making research and drug development opportunities available by synthesizing pharmaceutical grade ibogaine and developing preclinical evidence to support an improved understanding of ibogaine's medical potential.

Why We Synthesize

Ibogaine is a psychoactive substance traditionally extracted from the West African iboga shrub.

Research exhibiting ibogaine’s powerful and unique effects on multiple receptors and neurotransmitter systems present exciting opportunities to improve the quality of life for many. These opportunities are limited by the lack of access to a sustainable and consistent supply.

Creating an Opportunity for Psychedelic Researchers

MINDCURE is manufacturing pharmaceutical grade ibogaine to improve access for researchers and clinicians working to create safe and effective treatment options for patients with key indications. The natural source from which ibogaine derives has high natural variability, which poses challenges for the purposes of psychedelic drug research.

With a reliable supply at a known purity, MINDCURE solves the issue of inaccessibility by supplying researchers with the materials needed for preclinical and clinical studies.

Creating an Environmentally Friendly & Sustainable Supply

As a leader in psychedelics, MINDCURE recognizes the value of the iboga plant as a rare and diminishing resource. Our sustainable approach to manufacturing synthetic ibogaine enables us to provide approved research partners and treatment facilities with access to a safe, reliable, and efficacious supply to help drive towards and create better treatment outcomes without further endangering the iboga plant.

In Q2 of 2022, MINDCURE expects to have our GLP material available. At this point, our research team will gain access to consistent and patented materials with our proprietary synthesis of ibogaine hydrochloride, to be used in our own preclinical trials.

History of Ibogaine

1864

The first scientifically recorded sample is collected in Gabon, brought to France

1889

The genus Tabernanthe H.Bn is established

1901

Crystalized alkaloids are isolated from iboga roots, named ibogaine

1901 – 1905

Ibogaine hydrochloride is used at a dose of 10-30mg/day for anti-fatigue

1930

Lambarene enters market to treat depression, asthenia, convalescence, & infectious disease

1944

Delourme-Houde isolates Tabernanthe

1957

Atropine found to block arousal syndrome caused by ibogaine

1962

Studies confirm ibogaine’s effects on blood pressure and heart rates, reaffirmation that atropine prevents rise in blood pressure but doesn’t impact behavior

1966

Lambarene is removed from market

1969

Ibogaine’s antifatigue and anti-depressant benefits attributed to monoamine oxidase inhibitor

1985 – 1991

Howard Lotsof patents ibogaine for various substance dependencies

2021

MINDCURE successfully synthesizes Ibogaine

2022 Q1

MINDCURE intends to apply for provisional patents

2022 Q1

MINDCURE to start preclinical research

2022 Q2

MINDCURE’s GLP to be successfully completed

2022 Q3

MINDCURE to deliver GMP

A Growing Need

The need for ibogaine in both research and therapeutic settings will grow vastly over the years as scientists investigate and discover further indications. Potential therapeutic uses from preliminary data include:

Addiction

Traumatic Brain Injuries

Anxiety

Depression

Migraines

Cluster Headaches

Neuropathic Pain

Treatment-Resistant Mood Disorders

Potential therapeutic uses of ibogaine from preliminary data include:

Addiction

the drug, alcohol and other addictions treatment industry will be worth US$38.2B this year (5.2% annual growth in revenues)

Mood Disorders

the global anxiety and depression market is estimated to reach US$24.4B by 2030

Cognition & Repair

the cognitive enhancement market is estimated to reach US$6.5B by the end of 2023

What Peaple Say

Testimonials

We hope to create a care paradigm whereby MDMA-assisted psychotherapy becomes common practice for women suffering from decreased desire.

Juan Ruiz
Doctor

We hope to create a care paradigm whereby MDMA-assisted psychotherapy becomes common practice for women suffering from decreased desire.

Juan Ruiz
Doctor

We hope to create a care paradigm whereby MDMA-assisted psychotherapy becomes common practice for women suffering from decreased desire.

Juan Ruiz
Doctor

We hope to create a care paradigm whereby MDMA-assisted psychotherapy becomes common practice for women suffering from decreased desire.

Juan Ruiz
Doctor

Preclinical Research Development

MINDCURE is currently in the process of creating strategic preclinical testing models using ibogaine to identify mechanisms of action and expectations, understand cognitive benefits, measure cardiotoxicity and adverse effects, and establish safety measures, dosing, and methods of administration.

Given ibogaine’s complex pharmacology and the way in which it interacts in neurochemistry, our priority in developing preclinical models is in understanding the safety and efficacy for any indication for ibogaine. MINDCURE believes in securing an in-depth understanding of the mechanisms of action through specific preclinical models that outline ibogaine’s dose response on various pathways.

In leveraging the knowledge of ibogaine’s historical uses in the treatment of anxiety and depression as a starting point, our preclinical studies will help us understand, at a deeper level, the compound’s potential and direct our exploration into ibogaine’s potential future uses.

The Time to Invest in Ibogaine Is Now